

Synthesis of Tetrahydroimidizalone-Dihydropyrimidinone hybrids

Nathalia C. Silva,^{1*} Vinícius Vendrusculo,¹ Samuel J. Santos¹ and Dennis Russowsky¹

1. Laboratory of Organic Synthesis, Institute of Chemistry, Federal University of Rio Grande do Sul, 91501-970, Porto Alegre/Brazil


*e-mail: nathichagas16@gmail.com

Keywords: Molecular Hybridization, Tetrahydroindazolones, Dihydropyrimidinones.

ABSTRACT

Tetrahydroimidizalones (THIz) are important scaffolds in Medicinal Chemistry. They are active as protein kinases inhibitors,¹ anti-cancer agents² or antimicrobials.³ Likewise, Dihydropyrimidinones (DHPM) are cytotoxic against several cancer cell lines.⁴

The hybridization of these two heterocyclic compounds may lead to the discovery of more efficient drugs with reduced side effects.⁵ Thus, the easy access of THIz from the reaction of enamino-hydrazine **1** and substituted aldehydes **2a-e**, prompt us to prepare a set of 2,3-diaryl-tetrahydroindazol-4-ones **5a-e** in good yields. The click CuAAC reaction⁶ of THIz **5e** and azido-DHPM **6** afforded the hybrid compound **7e** with a non hydrolyzable triazole link in 81% yield after purification (Scheme 1 and Table 1).



Scheme 1: General scheme for the synthesis of THIz-DHPM hybrid compounds **7e**.

Table 1. Yield of compounds **5a-e** and hybrid THIz-DHPM **7e**

Entry	Compound	R1	R2	R3	Yield (%)
1	5a	H	H	H	70
2	5b	H	OMe	H	69
3	5c	H	OMe	OMe	72
4	5d	OMe	OMe	OMe	75
5	5e	H	OPropargyl	H	77
6	7e	-	-	-	79

The antibacterial and anticancer activities of THIz and THIz-DHPM hybrid against Gram positive/negative and a set of tumoral cell lines, respectively, are under current investigation.

ACKNOWLEDGEMENTS

The authors acknowledge Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), for the financial support and fellowships.

REFERENCES

- (1) Kumar, A.; Ahmad, I.; Chhikara, B. S.; Tiwari, R.; Mandal, D.; Parang, K. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 1342.
- (2) Khlebnicov, T. S.; Zinovich, V. G.; Piven, Y. A.; Baranovsky, V. A.; Lakhvich, F. A.; Trifonov, R. E.; Golubeva Y. A., Liderc, E. V. *Russ. J. Gen. Chem.* **2022**, *92*, 359.
- (3) Laczkowski, K. Z.; Misiura, K.; Biernasiuk, A.; Malm, A. *Lett. Drug Des. Discov.* **2014**, *11*, 960.
- (4) Matos, L.H.S., Masson, F.T; Simeoni, L. A.; Homem-de-Mello, M. *Eur. J. Med. Chem.* **2018**, *143*, 1779.
- (5) *Design of Hybrid Molecules for Drug Development*, Decker, M. Ed.; Elsevier, Radarweg 29, Amsterdam, Netherlands, 2017.
- (6) Kasana, S.; Nigam, V.; Singh, S.; Kurmi, B. D.; Patel, P. *Chem. Biodivers.* **2024**, *6*, e202400109.